研究 | 设计 | ORR% | PFS or TTP (月) | OS (月) | 治疗 | 参考 文献 |
EMILIA | 随机试验,三期,晚期大于等于二线,局部进展或转移性乳腺癌 | NA | NA | 29·9 | T-DM1 | [42] |
CLEOPATRA | 随机试验,三期,晚期一线,局部进展或转移性乳腺癌 | 80.2 | 18.5 | 56.5 | Docetaxel + Trastuzumab + Pertuzumab | [40] |
MonarcHER | 随机试验,二期,晚期大于等于二线,局部进展或转移性乳腺癌 | 1.33 2.14 3.14 | 1.8.3 2.5.7 3.5.7 | NA | 1. Abemaciclib + trastuzumab + fulvestrant 2. Abemaciclib + trastuzumab 3. Standard-of-care + trastuzumab | [43] |
TDM 4450 g | 随机试验,三期,晚期一线,转移性乳腺癌 | 64.2 | 14.2 | NA | T-DM1 | [44] |
ALLIANCE | 随机试验,三期,晚期一线,局部进展或转移性乳腺癌 | 1.38% 2.17% | 1.5.9 2.3.3 | NA | 1. lapatinib + fulvestrant 2. fulvestrant | [45] |
ALTERNATIVE | 随机试验,三期,晚期一线,局部进展或转移性乳腺癌 | 1.38 2.16 3.22 | 1.11 2.5.7 3.8.3 | 1.46 2.40 3.45.1 | 1. Trastuzumab + lapatinib + AI 2. Trastuzumab + AI 3. lapatinib + AI | [39] |
BOLERO-1 (亚洲人群) | 随机试验,三期,晚期一线,局部进展或转移性乳腺癌 | NA | 1.18.4 (HR-亚组25.46) 2.18.2 (HR-亚组14.49) | NA | 1. Everolimus + Paclitaxel + Trasyuzumab 2. Paclitaxel + Trasyuzumab | [46] |
PERTAIN | 随机试验,二期,晚期一线,转移性乳腺癌 | NA | 1.18.89 2.15.8 | NA | 1. pertuzumab + trastuzumab + AI 2. trastuzumab + AI | [47] |
TH3RESA | 随机试验,三期,晚期晚期大于等于二线,局部进展或转移性乳腺癌, | NA | 6.2 (HR+亚组5.9 HR-亚组6.0) | 22.7 (HR+亚组26.3HR-亚组21.1) | T-DM1 | [48] |